Pilocarpine (DrugBank: Pilocarpine)
3 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 2 |
53 | Sjogren syndrome | 5 |
299 | Cystic fibrosis | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-jRCTs041180018 | 04/09/2017 | 20/12/2018 | Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease | Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease - Pupillary autonomic dysfunction and visual hallucination in Parkinson's disease | Parkinson's disease and related diseases | Two drops of 0.05% pilocarpine hydrochloride, which is a parasympathomimetic agent, on the right eye, 2 drops of 0.04% dipivefrin hydrochloride, which is a sympathomimetic agent, to the left eye | katsuno Masahisa | NULL | Recruiting | >= 40age old | Not applicable | Both | 40 | Phase 2 | Japan |
2 | JPRN-UMIN000026128 | 2017/04/01 | 01/04/2017 | Association between pupillary autonomic dysfunction and visual hallucination in Parkinson's disease | Parkinson's disease | administe pilocarpine and dipivefrine administe pilocarpine and dipivefrine | Nagoya University | NULL | Recruiting | 40years-old | 90years-old | Male and Female | 60 | Not selected | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000010796 | 2013/06/01 | 24/05/2013 | Impact of CYP2A6 and CHRM3 genetic polymorphisms on the PK/PD of pilocarpine in Japanese healthy volunteers | Sjogren's syndrome | single oral administration of pilocarpine. salagen (KISSEI PHARMACEUTICAL CO.,LTD.) 5mg 1Tablet. | Oita University Faculty of Medicine | NULL | Pending | 20years-old | Not applicable | Male and Female | 30 | Not applicable | Japan | |
2 | JPRN-UMIN000029307 | 2009/02/01 | 27/09/2017 | Efficacy and safety of pilocarpine / sodium alginate formulation for dry mouth in Sjogren's syndrome patients | Sjogren's syndrome | Pilocarpine / sodium alginate solution (0.32 mL, pilocarpine 0.96 mg) is administered intra-orally 3 times a day for 7 days. | Teikyo University | NULL | Complete: follow-up complete | 16years-old | Not applicable | Male and Female | 50 | Not selected | Japan | |
3 | JPRN-UMIN000001460 | 2008/10/01 | 29/10/2008 | The efficacy and safety of pirocarpine hydrochloride for juvenile Sjogren's syndrome | Sjogren's syndrome | Oral pilocarpine hydrochloride for 4 weeks. | Department of Pediatrics, Graduate School of Medicine, Chiba Univerity | NULL | Complete: follow-up complete | 6years-old | 16years-old | Male and Female | 10 | Not selected | Japan | |
4 | NCT00438048 (ClinicalTrials.gov) | November 2006 | 20/2/2007 | A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment | Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva | Primary Sjogren;Secondary Sjogren;Xerostomia | Procedure: pilocarpine;Drug: Artificial Saliva | Pontificia Universidad Catolica de Chile | Formulario MAgistral Farmacias Ahumada | Completed | 18 Years | N/A | Both | 76 | Phase 4 | Chile |
5 | NCT04470479 (ClinicalTrials.gov) | March 1, 2005 | 7/7/2020 | Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome | Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome | Dry Eye | Drug: Pilocarpine Hydrochloride;Drug: Placebo | Federal University of São Paulo | NULL | Completed | 18 Years | 65 Years | All | 32 | Phase 3 | Brazil |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03584841 (ClinicalTrials.gov) | March 31, 2017 | 27/5/2018 | Implementation of a Non-invasive Version of the Imaging ß-adrenergic-dependent Sweat Secretion Test | Implementation of a Non-invasive Version of the Imaging ß-adrenergic-dependent Sweat Secretion Test: Value for Diagnosis and Efficacy of Target Therapies for Cystic Fibrosis | Mucoviscidosis Involving the Lung | Diagnostic Test: Iontophoresis sessions in forearm of subjects with pilocarpine | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | NULL | Recruiting | 18 Years | 100 Years | All | 120 | N/A | Belgium |
2 | NCT02310789 (ClinicalTrials.gov) | July 31, 2015 | 3/9/2014 | (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil? | (Study: Vertex IIS) A Study To Access the Effects of Ivacaftor on Wild Type CFTR-Open Probability (PO) In The Sweat Gland Secretory Coil | Cystic Fibrosis | Drug: Ivacaftor;Drug: ß-Adrenergic cocktail;Drug: Pilocarpine Nitrate 5%;Device: Macroduct sweat stimulator | Richard Barry Moss | NULL | Completed | 18 Years | N/A | All | 8 | N/A | United States |